Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $175 | $282 | $111 | $38 |
| Short-Term Investments | $155 | $57 | $20 | $51 |
| Receivables | $18 | $22 | $15 | $68 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $6 | $4 | $4 |
| Total Curr. Assets | $355 | $366 | $150 | $161 |
| Property Plant & Equip (Net) | $32 | $33 | $34 | $36 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $26 | $27 | $159 | $157 |
| Total NC Assets | $61 | $60 | $193 | $193 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $415 | $426 | $344 | $354 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $2 | $2 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $27 | $6 | $6 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $0 | $0 |
| Total Curr. Liab. | $37 | $55 | $32 | $32 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $112 | $111 | $109 | $107 |
| Total NC Liab. | $145 | $147 | $146 | $147 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $34 | $46 | $48 | $50 |
| Total Liabilities | $183 | $201 | $178 | $179 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$921 | -$924 | -$979 | -$966 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $233 | $225 | $166 | $176 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $415 | $426 | $344 | $354 |
| Net Debt | -$175 | -$282 | -$111 | -$38 |